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Tumor-infiltrating lymphocytes (TILs) have been reported as a prognostic factor in various cancers and are a promising target
for immunotherapy. To investigate whether TILs have any impact on the prognosis of angiosarcoma patients, 55 non-treated
patients (40 patients at stage 1 with cutaneous localized tumors, 4 patients at stage 2 with lymph node metastases and 11
patients at stage 3 with distant metastases) with angiosarcoma were evaluated retrospectively by immunohistochemistry
stained CD4, CD8, FOXP3 and Ki67. The Kaplan–Meier method was used to estimate overall survival with patients at stage 1.
Survival differences were analyzed by the log-rank test. Patients with higher numbers of CD81 TILs in their primary tumors
survived significantly longer compared with patients with lower values. Moreover, the number of CD8 in TILs was positively
correlated with a distant metastasis-free period. The total number of primary TILs (CD4 plus CD8) and CD81 primary TILs of
stage 3 patients with distant metastases was positively correlated with their overall survival. To evaluate whether CD81 effec-
tor T cells are activated or differentiated, flow cytometric analysis of peripheral blood mononuclear cells (PBMC) was per-
formed. The percentages of CD81 T cells producing IFN-c in PBMC were significantly higher in patients with angiosarcoma
(n510) compared not only with that of healthy controls (n520) but also patients with advanced melanoma (n511). These
results suggest that anti-tumor immunity is clinically relevant in angiosarcoma.
Cutaneous angiosarcoma is a rare soft-tissue sarcoma of endo-
thelial cell origin that has a poor prognosis.1 Although angio-
sarcoma can arise anywhere in the body, it often arises on the
face and scalp, leading to a poor prognosis and decreased qual-
ity of life. Chemotherapies and radiotherapies are options for
angiosarcoma treatment; however, unfortunately, there is no
treatment that cures angiosarcoma except complete resection,
which is often not possible. A more effective therapy is
required to improve the prognosis of angiosarcoma, and
immunotherapy may be one of the candidate therapies. Indeed,
some previous studies suggest the importance of tumor immu-
nity in the progression of angiosarcoma. Maddox and Evans
reported that in patients with angiosarcoma, those with moder-
ate or marked inﬂammation in tumors showed signiﬁcantly
better survival compared with those with slight or no inﬂam-
mation.2 Furue et al. reported a case of angiosarcoma in which
immunotherapy using tumor-inﬁltrating lymphocytes (TILs)
for Stewart–Treves syndrome dramatically improved the clini-
cal symptoms.3 Zietz et al. reported that angiosarcoma with
low Fas-L expression was characterized by numerous TILs and
the survival durations of patients with high Fas-L expressing
angiosarcomas were signiﬁcantly reduced compared to patients
with low Fas-L-expressing tumors.4 These reports suggest the
importance of TILs in the prognosis of angiosarcoma patients,
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and that the evaluation of tumor immunity may be possible by
analyzing TILs.
Recent clinical experience in immunotherapy indicates
that anti-tumor immunity mediated by T cells can have a
strong impact on the clinical course of certain tumors.5–7
Effective cancer immunotherapy is dependent on the pres-
ence of large numbers of anti-tumor lymphocytes with
appropriate homing and effector functions that enable them
to seek out and destroy cancer cells in vivo.5 TILs have been
reported as one of the representative manifestations of host
anti-tumor immune response and as a target for immuno-
therapy.5,8,9 Indeed, TILs are associated with the prognosis of
various cancers.10–15 In addition, the analysis of T cell subsets
in TILs can provide a deeper insight into anti-tumor immu-
nity. In particular, CD81 effector T cells in TILs have associ-
ations with the prognosis of various cancers.12,14,16–20
Conversely, the ratio of FOXP31 regulatory T cells (Tregs) in
TILs is reported to have correlations with a worse prognosis
in patients with certain cancers.21,22
Although tumor immunity can have an impact on the
prognosis of angiosarcoma, the lymphocyte subsets of TILs
and peripheral blood mononuclear cells (PBMC) in angiosar-
coma patients have not been fully characterized. In this
study, by means of immunohistochemistry, we have investi-
gated whether the subsets of TILs have correlations with the
clinical course or prognosis of patients with angiosarcoma.
Moreover, to compare the frequencies of effector T cells in
peripheral blood with healthy controls and other malignant
cutaneous tumors, the percentage and IFN-g production of
CD81, CD41 T cells in PBMC of angiosarcoma, melanoma




Blood and tissue samples were obtained from Japanese patients
with angiosarcoma (fresh blood samples n5 10, parafﬁn-
embedded tissue samples n5 55), healthy controls (fresh blood
samples age-sex matched n5 20) and melanoma patients
(fresh blood samples, n5 11). We retrospectively checked
parafﬁn-embedded tissue samples (resected as biopsies or sur-
geries) and also medical records from Kyoto University Hospi-
tal, and found 29 patients with angiosarcoma from 1990 to
2012. In this article, we used tissues of non-treated primary
cutaneous tumors. Thus, we excluded four samples, which had
already received some treatment. We obtained 25 samples
from the University of the Ryukyu, 2 samples from Fukui Red
Cross Hospital and 3 samples from Kyoto City Hospital. Thus,
we arrived at a total of 55 samples.
This study was approved by the Medical Ethics Committee
of the Kyoto University Graduate School of Medicine, and was
conducted in accordance with the principles of the Declaration
of Helsinki. All patients and healthy controls provided written
informed consent to participate in the study.
Patient’s characteristics: clinical stages and the number of
TILs
There had been no certain clinical tumor staging strategy for
cutaneous angiosarcoma that reﬂected the prognosis or cura-
tive effect throughout the world. In this study, we classiﬁed
our patients groups simply into three stages by modifying
classic TNM classiﬁcation as reported previously, stage 1 for
those with cutaneous local tumors, 2 for those with lymph
node metastases and 3 for those with distant metastases,23,24
which reﬂected the patients’ prognosis. Our 55 non-treated
patients (40 stage 1, 4 stage 2 and 11 stage 3 patients) with
angiosarcoma were consistent with the previous report23,24
with the overall survival being different in each stage (Stage1-
> 2> 3) as estimated by the Kaplan–Meier method (data not
shown for stage 2).
Non-treated primary tumor specimens of 55 patients were
evaluated retrospectively by immunohistochemistry stained
CD4, CD8, FOXP3 (n5 55), MHC class1 (n5 52), Ki67
(n5 45) and CD31 (n5 51). We performed Ki67 staining as
a proliferation marker, calculating the Ki67-index of tumors,
and using CD31 staining as a vascular endothelial cell marker
to aid in the detection of tumors. Count data and patients’
characteristics are presented in Table 1.
Flow cytometric analysis
Flow cytometric analyses for PBMC of patients with
untreated stage 1 angiosarcoma were planned and performed
from 2007 to 2012 in Kyoto University Hospital. The total
sample number was 10. PBMC were isolated with Ficoll-
Isopaque (LymphoprepTM; Axis-Shield, Oslo, Norway) gradi-
ent centrifugation. PBMC were freshly stained and analyzed
with the following monoclonal antibodies as previously
described25: allophycocyanin (APC) conjugated anti-CD4
(clone 11830; R and D systems); ﬂuorescein isothiocyanate
(FITC)-conjugated anti-IFN-g (clone 4S.B3; BD Biosciences);
peridinin chlorophyll protein-Cy5.5 (PerCp-Cy5.5)-conju-
gated anti-CD8 (clone SK1; BD Biosciences).
What’s new?
Tumor-infiltrating lymphocytes (TILs) have been reported to be a prognostic factor in various cancers. In this study, the
authors investigated whether TILs have any impact on the prognosis of angiosarcoma. They found that higher numbers of
CD81 TILs correlated with both a longer period free of distant metastases, and a more favourable prognosis. PBMC analysis
showed that patients with angiosarcoma also had higher numbers of CD81 effector T cells than did healthy controls. TIL-
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Acquisition and data analysis were performed with FACS
Calibur (BD Biosciences) or LSR Fortessa (BD Biosciences)
and Flow Jo software (Tree Star).
Intracellular cytokine staining
Fresh PBMC (5 3 106 cells/well) in 24-well plates were
stimulated with 20 ng/ml PMA and 1 mM ionomycin in the
presence of protein transport inhibitor monensin (Golgi-Stop,
BD Biosciences) for 5 hr. Cells were harvested and co-stained
with anti-CD4 and anti-CD8 monoclonal antibodies for sur-
face staining. Then, cells were ﬁxed, permeabilized with Cyto-
ﬁx/Cytoperm (BD Biosciences) and stained with anti-IFN-g
monoclonal antibodies for intracellular staining prior to anal-
ysis by ﬂow cytometry.
Immunohistochemistry
Tumor-inﬁltrating lymphocytes (TILs) were characterized in
3 mm-thick serial sections cut from formalin-ﬁxed, parafﬁn-
embedded, tissue specimens of the most representative tumor
areas. Immunohistochemistry by autoclave antigen retrieval
methods was carried out as previously described.26 The fol-
lowing primary anti-human monoclonal antibodies were
used: anti-CD4 (clone 1F6; Novocastra, UK), anti-CD8 (clone
C8/144B; Dako, Denmark), anti-FOXP3 (clone 236A/E7;
eBioscience), anti-Ki67 (clone MM1; Novocastra, UK), anti-
CD31 (clone 1A10; Novocastra, UK) and anti-MHC class1
(anti-HLA class I [HLA-A, B, C], clone EMR8-5, MBL Tokyo
Japan).
Quantification of the tumor-infiltrating lymphocytes
In each immunostained serial section, the entire tumor area
was evaluated for TILs at a scanning power (253 objective
and 103 eyepiece). Areas with the most abundant TILs were
selected, and a maximum of ﬁve randomly chosen high
power ﬁeld (HPF) (403 objective and 103 eyepiece) were
digitally photographed and counted manually. The count was
performed two times for each photograph by the same inves-
tigator (H.F.) without knowledge of earlier results. In all
cases, absolute numbers of TILs (add CD41 T cell count and
CD81 T cell count), CD41, CD81, FOXP31 tumor inﬁltrate
lymphocytes per HPF, % FOXP3 lymphocyte ratio (FOXP31
T cell count divided by CD41 T cell count and expressed in
percentage terms), CD8/CD4 lymphocyte ratio (CD81 T cell
count divided by CD41 T cell count) and CD8 / FOXP3
(CD81 T cell count divided by FOXP31 T cell count) were
calculated. The average TILs count for each patient was used
for statistical analysis. The Ki67-index was also calculated.
All the immunohistochemical Ki67 stained glass slides were
reviewed by our dermatopathologist (S.S.). The Ki67-index of
tumor was deﬁned as the percentage of tumor cells staining
positive for the Ki67 antigen in the total number of tumor
cells, by counting multiple regions with highest labeling den-
sity. To keep the index quality, we excluded bad Ki67 stain-
ing sections, in which it was difﬁcult to distinguish tumor
cells from surrounding connected tissues, or in which more
than 500 tumor cells could not be counted.
Statistical analysis
Overall survival was measured as the time from the patient’s
ﬁrst visit to the hospital to the time of death or the time the
patient was last seen (until August 2012). For all immunohis-
tochemical markers, cutoff for deﬁnition of subgroups was
the median. The log-rank test was used to perform univariate
analyses and the survival curves were estimated by the
Kaplan–Meier method. The Mann–Whitney U-test was used
for comparing unpaired ﬂow cytometric data of two groups.
The Kruskal–Wallis H-test was used for multiple compari-
sons. Correlations were evaluated using the Spearman’s rank
correlation coefﬁcient. p values were two tailed and a p val-
ue< 0.05 was considered statistically signiﬁcant.
Results
Prognostic significance of primary TILs in patients with
stage 1 cutaneous angiosarcoma
To investigate whether the numbers of TILs and T cell sub-
sets of TILs at cutaneous primary sites have a relationship
with prognosis of patients with cutaneous angiosarcoma,
immunohistochemical analysis of TILs of angiosarcoma was
performed.
Figure 1a shows the survival curve of our 40 non-treated
stage 1 patients with angiosarcoma (Fig. 1a). Immunohisto-
chemical analysis of their primary tumors is done for CD31,
Ki67, MHC class 1, CD4, CD8 and FOXP3 (Fig. 1b). The
patients with stage 1 cutaneous angiosarcoma were divided
into two groups using the median value as the cutoff for
each variable. The prognostic signiﬁcance between the T cell
subsets of TILs and their overall survival was calculated by
the Kaplan–Meier method. Patients with higher numbers of
CD8/HPF (high power ﬁeld, high; n 5 20, low; n 5 20,
p5 0.019; Fig. 1c) in their primary tumors demonstrated
improved survival compared with patients with lower fre-
quencies. No signiﬁcant association was found for TILs/HPF
(Fig. 1c), CD4/HPF (Fig. 1c), FOXP3/HPF (Fig. 1c), ratio of
CD8/CD4, FOXP3/CD4 (%FOXP3), CD8/FOXP3 of T cell
subsets and Ki67-index of tumors (data not shown).
Next, to examine how the CD81 TILs contributed to the
better prognosis of patients with angiosarcoma, we evaluated
their disease-free survival. However, it was difﬁcult for most
patients to maintain tumor-free status because angiosarcoma
spreads with unclear borders, so we could not clearly evaluate
the disease-free survival. Clinical histories revealed that most
patients with angiosarcoma died from lung metastases.
Therefore, we chose to evaluate the relation between distant
metastases (mainly lung) and TILs. Indeed, the periods
between their initial visits to our hospital and distant metas-
tases (distant metastasis-free period) were closely correlated
with their overall survival (n5 18, p5 2.13E-06, r5 0.874;
data not shown). Moreover, CD8/HPF of TILs was positively
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Figure 1. Prognostic significance of primary TILs in patients with stage 1 cutaneous angiosarcoma. The survival curve of our 40 non-treated
stage 1 patients with angiosarcoma (a). Representative immunohistochemistry was presented (b). The stage 1 patients were divided into
two groups using the median value as the cutoff of each variable. The Kaplan–Meier method was used to estimate overall survival. Survival
differences were analyzed by the log-rank test based on the number of TILs (CD8/HPF plus CD4/HPF), its subsets CD8/HPF, CD4/HPF and
FOXP3/HPF (c). Correlation analysis was performed by Spearman rank correlation test with clinical parameters described below and frequen-
cies of TILs. Primary TILs in stage 1 patients were used for the statistic. There was positive correlation between the months from initial visit
to the hospital until patients developed distant metastases (in the graph, name as distant metastasis-free period) and the overall survival
period of those patients who were deceased (n518, data not shown). Correlation between distant metastasis-free period and the number
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p5 0.0113, r5 0.567; Fig. 1d). No other immunohistological
parameters had signiﬁcant correlations with the distant
metastasis-free period (Fig. 1d, and data not shown).
Significant correlation between primary TILs in stage 3
patients and overall survival
Next, we evaluated correlation analysis with the prognosis of
stage 3 patients who developed distant metastases, although
we could not assess stage 2 patients who developed lymph
node metastases because of the small number of patients.
Figure 2a shows the survival curve of our 11 non-treated
stage 3 patients with angiosarcoma (Fig. 2a).
All 11 patients with stage 3 angiosarcoma had already
died from the tumors. The number of primary TILs (CD4
plus CD8) and CD81 primary TILs of stage 3 patients was
positively correlated with their overall survival (TILs; n5 11,
p5 0.010, r5 0.734, Fig. 2b, CD8; n 511, p 50.0314,
r5 0.647, Fig. 2b).
The percentage of IFN-c production of CD81 T cells in
PBMC of patients with angiosarcoma
To evaluate whether T cells, especially CD8 effector T cells,
are activated or differentiated in patients with angiosarcoma,
we analyzed IFN-g production of CD41 and CD81 T cells in
peripheral blood mononuclear cells (PBMC) using ﬂow
cytometry in available non-treated patients with cutaneous
angiosarcoma (n5 10, stage1) and compared it with healthy
controls (HC, n5 20) and patients with malignant melanoma
(MM, n5 11, stages 3 and 4) as a disease control.
The percentages of CD81 T cells producing IFN-g in
PBMC were signiﬁcantly higher in patients with angiosar-
coma compared with those of healthy controls and patients
with melanoma (IFN-g; median, HC 56.0% vs. AS 76.8% vs.
MM 64.3%, p5 0.0295 compared three groups by Kruskal–
Wallis H-test, AS>HC, p5 0.0326, AS>MM p5 0.0296 by
Mann–Whitney U test. Fig. 3b). Moreover, the percentage of
IFN-g producing CD41 T cells was also signiﬁcantly higher
in angiosarcoma patients compared with those of healthy
controls, but was not signiﬁcant compared with those of mel-
anoma patients (IFN-g; median, HC 12.8% vs. AS 23.7% vs.
MM 16.5%, p5 0.00992 compared three groups by Kruskal–
Wallis H-test, AS>HC, p5 0.00324, AS>MM p5 0.0884
by Mann–Whitney U test, Fig. 3b).
These results indicated that PBMC in angiosarcoma
patients contained signiﬁcantly larger frequencies of CD81
and CD41 effector T cells.
Discussion
To the best of our knowledge, this study provides the ﬁrst
immunological data showing that primary CD81 TILs are
the most relevant T cell population in the prognosis of cuta-
neous angiosarcoma. Previous reports2,4 showed that higher
numbers of TILs correlated with a favorable prognosis in
patients with angiosarcoma. Our study examined
Figure 2. Significant correlation between primary TILs in stage 3 patients and overall survival. The survival curve of our 11 non-treated stage
3 patients with angiosarcoma (a). Correlation analysis was performed by spearman rank correlation test with overall survival and frequen-
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immunological parameters of TILs including CD4, CD8,
FOXP3 and found that CD8 is the most possible prognostic
factor.
Galon et al. proposed a new cancer classiﬁcation using
“immunoscore,” which is a tool including immunological bio-
markers to predict prognosis and response to therapy.27 The
study stated that immunoscore should be incorporated into
the traditional TNM classiﬁcation. Our results indicated that
tumor-inﬁltrated CD8 can be one parameter of the immuno-
score in patients with angiosarcoma.
In our data, higher numbers of CD81 TILs resulted in a
longer distant metastasis-free period. This result suggested
that CD81 cytotoxic T lymphocytes in TILs are important in
suppressing progression of angiosarcoma. It has been demon-
strated in animal models that inﬁltration of tumors by
tumor-reactive T lymphocytes is required for efﬁcient tumor
regression28,29 and the concentration of CD81 T cells deter-
mined the efﬁciency of target cell killing.30 In human studies,
accumulating evidence has shown that tumor inﬁltration by
CD81 T cells is associated with a better prognosis in various
cancers, such as bladder cancer,12 renal cell carcinoma,16
colorectal cancer,14 ovarian cancer,17,18 esophageal carci-
noma19 and hepatocellular carcinoma.20 CD81 cytotoxic T
lymphocytes recognizing tumor antigens are also found in
human melanoma-speciﬁc TILs,31 and CD81 TILs cultured
from metastatic melanoma exerted lytic activity on autolo-
gous melanoma cells.31,32 Therefore, tumor inﬁltrating
CD81T lymphocytes have been recognized to have anti-
tumor effects on cancer patients. Together with our data, the
contribution of CD81 TILs to the favorable prognosis in
angiosarcoma seemed mostly due to the ability of CD81 T
cells as tumor antigen-speciﬁc cytotoxic T lymphocytes to kill
target cells directly, although the in vitro ionomycin assay
evaluated in this study is only by PBMC and is not a conclu-
sive experiment to prove the speculation.
To recognize a tumor, CD81 T cells need the expression
of MHC class 1 on tumor cells. It was previously reported,
through the analysis of a few cases, that angiosarcoma
expressed both MHC class 1 and cancer-testis-antigen.33 In
this report, all the analyzed samples of angiosarcoma
expressed MHC class 1 (n5 52 data not shown). After recog-
nition of a tumor, one of the mechanisms of tumor lysis by
CD81 cytotoxic T lymphocytes is induced by Fas-ligand, and
the expression of Fas-ligand in angiosarcoma by
Figure 3. The percentage of IFN-g production of CD81 T cell in PBMC of patients with angiosarcoma. Freshly isolated PBMC from patients
with angiosarcoma (AS; n510, stage 1), healthy controls (HC; n520, age-matched) and patient with malignant melanoma (MM; n511,
stages 3 and 4) were stimulated with PMA and ionomycin combined with a protein transport inhibitor for 5 hr. Cells were co-stained with
anti-CD4, -CD8 and anti-IFN-g antibodies, and analyzed by flow cytometry. Representative flow cytometric histograms of IFN-g1 cells in
CD81 T cells (a). Percentages of cytokine-positive cells were shown. The percentages of IFN-g1 cells in CD81 T cells (AS; n510, HC;
n520, MM; n511), or in CD41 T cells (AS; n510, HC; n520, MM; n511) were shown (b). The Kruskal–Wallis H-test was used for multi-
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immunohistochemistry has also been previously reported.4
Thus, direct recognition and lysis of tumors by CD81 cyto-
toxic T lymphocytes seem to be possible in our cases.
In addition, our PBMC analysis suggests that CD81 T
cells are systemically activated and differentiated in most of
the patients analyzed when compared with healthy controls
and melanoma patients (Fig. 3b), indicating that angiosar-
coma patients had more CD81 cytotoxic T lymphocytes in
PBMC. There is a possibility that anti-tumor immunity was
activated in angiosarcoma and it seemed not to be immuno-
suppressive, although we have to highlight the limitations of
the in vitro ionomycin assay.
Our data suggest that there might be certain tumor
immunity against angiosarcoma and if we can activate CD81
TILs in the tumor-microenvironment and succeed in sup-
pressing tumor growth locally, it might prevent tumor metas-
tases and contribute to a favorable prognosis for patients
with angiosarcoma. Furthermore, from our data, even if
patients develop distant metastases, it still seems important
that higher numbers of CD81 TILs at primary site contrib-
uted to their overall survival. There remains a strong possibil-
ity that immunological modiﬁcation of TILs in the tumor-
microenvironment may lead to new treatment strategies of
angiosarcoma.
The tumor-inﬁltrating CD41 T cells and FOXP31 T cells
were not signiﬁcantly associated with the prognosis of
patients with angiosarcoma in our data, even though suppres-
sion of anti-tumor immunity by Tregs is one of the impor-
tant factors in tumor progression.22 One possible explanation
is that CD41 helper T cells have functionally different sub-
sets such as T-helper 1 (Th1) cells, T-helper 2 (Th2) cells
and immunosuppressive Tregs. Furthermore, all FOXP3-
positive cells are not Tregs,25 because FOXP31 T cells have
functionally different subsets. These subsets have been shown
to have opposite inﬂuences against tumor-immunity. The
balances of these subsets are important for an anti-tumor
effect.34–36 In our data, the production of IFN-g in CD41 T
cells (ascribed as Th1) signiﬁcantly increased and percentages
of elevated CD41 FOXP31 T cells (data not shown) in the
peripheral blood of patients with angiosarcoma. Thus, there
was a possibility that both anti-tumor Th1 and immunosup-
pressive Tregs were increased in the tumor microenviron-
ment and were well-balanced.
Donghi et al.37 reported that by analyzing nine patients with
the Ki67-index of angiosarcoma, there was a tendency that the
patients with the most unfavorable course showed a strong
expression of Ki-67, while those with the best outcome only had
a slight positive Ki-67 staining. The data from the 30-patient
group we analyzed showed no statistically signiﬁcant differences
between the prognosis and Ki67-index of angiosarcoma, but
there were tendencies that the groups with a lower Ki67-index
had longer survival (data not shown). In this report, we could
not include all the stained sections for Ki67-index count due to
exclusion criteria. Thus, there is still a possibility that the Ki67-
index of tumors is prognostically important for patients with
angiosarcoma. Further investigation is required.
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